2018
Optical coherence tomography substudy of a prospective multicentre randomised post-market trial to assess the safety and effectiveness of the Firehawk cobalt-chromium coronary stent (rapamycin target-eluting) system for the treatment of atherosclerotic lesions: TARGET All Comers.
Baumbach A, Lansky AJ, Onuma Y, Asano T, Johnson T, Anderson R, Kiemeneij F, Zheng M, Van Royen N, Slagboom T, Vlachojannis G, Xu B, Serruys P, Wijns W. Optical coherence tomography substudy of a prospective multicentre randomised post-market trial to assess the safety and effectiveness of the Firehawk cobalt-chromium coronary stent (rapamycin target-eluting) system for the treatment of atherosclerotic lesions: TARGET All Comers. EuroIntervention 2018, 14: 1121-1128. PMID: 29901441, DOI: 10.4244/eij-d-18-00226.Peer-Reviewed Original ResearchConceptsOptical coherence tomography substudyPrimary endpointProspective multicentreStrut coveragePost-market trialDP-DESNeointimal thicknessDurable polymer drug-eluting stentsComers patient populationComplete strut coverageLate DES thrombosisSirolimus-eluting stentsStent strut coverageMean neointimal thicknessCoronary stent systemDrug-eluting stentsOCT substudyConsecutive patientsDES thrombosisPersistent inflammationPatient populationBP-DESNeointimal coverageEndothelial healingAtherosclerotic lesions
2008
Contemporary outcomes of rescue percutaneous coronary intervention for acute myocardial infarction: Comparison with primary angioplasty and the role of distal protection devices (EMERALD trial)
Dangas G, Stone GW, Weinberg MD, Webb J, Cox DA, Brodie BR, Krucoff MW, Gibbons RJ, Lansky AJ, Mehran R, Investigators F. Contemporary outcomes of rescue percutaneous coronary intervention for acute myocardial infarction: Comparison with primary angioplasty and the role of distal protection devices (EMERALD trial). American Heart Journal 2008, 155: 1090-1096. PMID: 18513524, DOI: 10.1016/j.ahj.2007.12.003.Peer-Reviewed Original ResearchConceptsST-segment resolutionTIMI 3 flowDistal protection devicesPrimary PCIDistal protectionInfarct sizeRescue PCIPost-procedural TIMI 3 flowRescue percutaneous coronary interventionComplete ST-segment resolutionSimilar myocardial perfusionPercutaneous coronary interventionST-elevation MIAcute myocardial infarctionHigher baseline ratesPrespecified comparisonPCI patientsPrimary angioplastyMonth mortalityPrimary endpointCoronary interventionClinical outcomesMulticenter trialClinical eventsPatient population
2005
Angiographic and clinical outcomes at 8 months of cutting balloon angioplasty and β‐brachytherapy for native vessel in‐stent restenosis (BETACUT): Results from a stopped randomized controlled trial
Schlüter M, Tübler T, Lansky AJ, Kähler S, Berger J, Mathey DG, Schofer J. Angiographic and clinical outcomes at 8 months of cutting balloon angioplasty and β‐brachytherapy for native vessel in‐stent restenosis (BETACUT): Results from a stopped randomized controlled trial. Catheterization And Cardiovascular Interventions 2005, 66: 320-326. PMID: 16216024, DOI: 10.1002/ccd.20517.Peer-Reviewed Original ResearchConceptsStandard balloonClinical outcomesCB angioplastyBalloon angioplastyStent restenosisInterim analysisMajor adverse cardiac eventsNative vesselsAdverse cardiac eventsOverall patient populationImmediate angiographic outcomeTreatment of choiceQuantitative coronary angiographyΒ-brachytherapyAngiographic restenosisBeta-radiation treatmentLesion revascularizationAngiographic outcomesCardiac eventsConsecutive patientsCoronary angiographyStudy armsIntracoronary brachytherapyPatient populationTreatment modalities
2004
Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: Design and rationale of the SYNERGY Library
Petersen JL, Mahaffey KW, Becker RC, Goodman SG, Kleiman NS, Marian AJ, Stone GW, Lansky AJ, Lincoff AM, Hazen SL, Nessel CC, Toro-Figueroa L, Tate L, Reist CJ, Cohen M, Califf RM, Ferguson JJ. Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: Design and rationale of the SYNERGY Library. American Heart Journal 2004, 148: 269-276. PMID: 15308996, DOI: 10.1016/j.ahj.2004.03.022.Peer-Reviewed Original ResearchConceptsAcute coronary syndromeHigh-risk patientsCoronary syndromeClinical trialsGlycoprotein IIb/IIIa Inhibitors (SYNERGY) trialSegment elevation acute coronary syndromesElevation acute coronary syndromeCore laboratory facilityEffect of enoxaparinCardiovascular clinical trialsNovel pharmacologic targetsHigh-risk conditionsFurther drug developmentSYNERGY patientsInflammatory markersInhibitor trialsMulticenter trialCoronary arteriogramsUnfractionated heparinPatient populationMyocardial infarctionCoagulation studiesPharmacologic targetPatientsEnoxaparin